KALA PHARMACEUTICALS INC's ticker is KALA and the CUSIP is 483119103. A total of 77 filers reported holding KALA PHARMACEUTICALS INC in Q1 2019. The put-call ratio across all filers is - and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $97,000 | -9.3% | 436,800 | +22.8% | 0.00% | – |
| Q2 2022 | $107,000 | -70.4% | 355,600 | +35.9% | 0.00% | – |
| Q1 2022 | $361,000 | +137.5% | 261,700 | +107.9% | 0.00% | – |
| Q4 2021 | $152,000 | -65.1% | 125,900 | -24.2% | 0.00% | -100.0% |
| Q3 2021 | $435,000 | -33.5% | 166,100 | +72.1% | 0.00% | 0.0% |
| Q4 2020 | $654,000 | +261.3% | 96,516 | +462.0% | 0.00% | – |
| Q2 2020 | $181,000 | -82.3% | 17,175 | -85.3% | 0.00% | -100.0% |
| Q1 2020 | $1,024,000 | +296.9% | 116,479 | +187.6% | 0.00% | – |
| Q2 2019 | $258,000 | -72.1% | 40,500 | -63.8% | 0.00% | -100.0% |
| Q1 2019 | $926,000 | -34.9% | 112,000 | -61.5% | 0.00% | -50.0% |
| Q4 2018 | $1,423,000 | +226.4% | 291,061 | +558.5% | 0.00% | – |
| Q3 2018 | $436,000 | – | 44,200 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CAXTON CORP | 1,430,021 | $9,638,000 | 6.26% |
| RA Capital Management | 10,874,613 | $73,295,000 | 1.10% |
| Mesirow Financial Investment Management, Inc. | 41,961 | $283,000 | 0.77% |
| Samsara BioCapital, LLC | 601,162 | $4,052,000 | 0.75% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 102,198 | $689,000 | 0.38% |
| Eventide Asset Management | 3,450,000 | $23,253,000 | 0.34% |
| Orbimed Advisors | 5,465,030 | $36,834,000 | 0.34% |
| Parkman Healthcare Partners LLC | 148,433 | $1,000,000 | 0.23% |
| Vivo Capital, LLC | 786,883 | $5,304,000 | 0.19% |
| Knights of Columbus Asset Advisors LLC | 199,954 | $1,348,000 | 0.13% |